Background: Recent studies have suggested a transient glucose hypermetabolism in early phases of Alzheimer's Disease (AD), which is followed by a characteristic glucose hypometabolism in dementia stages. This phenomenon desveres further investigation and it is suggested to be associated to glial/inflammatory or compensatory neuronal responses. Here, we aimed to longitudinally investigate brain glucose metabolism in an AD animal model and explore associated cellular and inflammatory changes.
Method: Longitudinal assessments, including cerebral glucose metabolism (18F]FDG-PET), behavioral tasks and cerebrospinal fluid (CSF) sample collection were performed at 3, 6, 9, and 12 months of age (mo) in wild type (WT) and TgF344-AD rats (Tg). Glial and inflammatory markers were evaluated in the CSF via ELISA multiplex. A cross-sectional cohort was used to follow the spatial distribution of Aß plaques (IHC), to assess the brain content of glial and neuronal proteins (western blot), and to analyze the cortical glutamate uptake (ex-vivo slices) at the same time points.
Result: At 9mo, three months after the initial appearance of Aß plaque deposits, Tg animals exhibited cortical glucose hypermetabolism (Figure 1A-C). At the same age, astrocytic glutamate uptake was increased in the cortex and hippocampus (Figure 2). Declines in performance on the Y-maze and Novel Object Recognition tasks were observed at 9 and 12mo (Figure 1D). CSF analysis revealed elevated GFAP levels at 6, 9 and 12mo, and reduced S100B at 9mo (Figure 1E e F). Tissue GFAP immunocontent increased in the temporoparietal cortex at 6 and 9mo, in the hippocampus at 9mo, and was reduced in the frontal and temporoparietal cortices at 12mo (Figure 3).
Conclusion: Our findings suggest the presence of an early, transient phase of brain glucose hypermetabolism in TgF344-AD rats, consistent with observations in recent animal and human studies. This phenomenon seems to be closely linked to the astrocyte response, reflected in variations of crucial astrocyte proteins such as GFAP and S100B, along with an increase in the glutamate uptake by these cells. In contrast, neuronal, microglial and inflammatory markers did not exhibit changes during this timeframe.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.094050 | DOI Listing |
Alzheimers Dement
December 2024
Federal University of Rio Grande do Sul, Brazil, Porto Alegre, RS, Brazil.
Background: The COVID-19 pandemic is a public health crisis, and its lasting consequences are not yet fully understood. Epidemiological data suggest that low- and middle-income countries, such as Brazil, will bear a considerable burden of COVID-19-related comorbidities. Individuals who have survived COVID-19 often report persistent symptoms, including neurological manifestations such as brain fog.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Background: Imaging biomarkers have helped to reconceptualize Alzheimer's disease pathophysiology. More specifically, positron emission tomography (PET) radiopharmaceuticals for non-invasively assessing amyloid-beta (Aβ) plaques, glucose metabolism, and glial reactivity allow for tracking disease progression in a temporally ordered manner. However, whether transgenic models recapitulate biomarker-related changes remains elusive.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Background: Imaging biomarkers have helped to reconceptualize Alzheimer's disease pathophysiology. More specifically, positron emission tomography (PET) radiopharmaceuticals for non-invasively assessing amyloid-beta (Aß) plaques, glucose metabolism, and glial reactivity allow for tracking disease progression in a temporally ordered manner. However, whether transgenic models recapitulate biomarker-related changes remains elusive.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, Irvine, Irvine, CA, USA.
Background: Recent studies have suggested a transient glucose hypermetabolism in early phases of Alzheimer's Disease (AD), which is followed by a characteristic glucose hypometabolism in dementia stages. This phenomenon desveres further investigation and it is suggested to be associated to glial/inflammatory or compensatory neuronal responses. Here, we aimed to longitudinally investigate brain glucose metabolism in an AD animal model and explore associated cellular and inflammatory changes.
View Article and Find Full Text PDFAnn Neurol
December 2024
Department of Neurology, Washington University School of Medicine, St. Louis, MO.
Objective: Despite treatments which reduce relapses in multiple sclerosis (MS), many patients continue to experience progressive disability accumulation. MS is associated with metabolic disruptions and cerebral metabolic stress predisposes to tissue injury and possibly impaired remyelination. Additionally, myelin homeostasis is metabolically expensive and reliant on glycolysis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!